News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Almirall Prodesfarma Key Drug Trials Disappoint Investors
September 3, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MADRID, Sept 3 (Reuters) - Spanish drug firm Almirall said the results of advanced trials for its key lung disease drug showed it was less effective than in previous trials, sending shares plummeting 18 percent.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Asia
Europe
MORE ON THIS TOPIC
Obesity
Lilly’s Zepbound Secures “Superior Benefit-Risk Ratio” Over Novo’s Wegovy
May 12, 2025
·
2 min read
·
Tristan Manalac
Manufacturing
Roche makes $300M China Production Promise After Multibillion US Investment
May 12, 2025
·
2 min read
·
Tristan Manalac
PARTNERED
Where AI Adds Real Value in Clinical Development
May 12, 2025
·
7 min read
·
BioSpace Insights
Drug Development
Eroding Immunity: Vaccine Hesitancy and Cynicism With Paul Offit
May 8, 2025
·
1 min read
·
Lori Ellis